About Eukaryotic initiation factor 4A-I
Eukaryotic initiation factor 4A-I (EIF4A1) is a protein
from Homo sapiens identified by UniProt accession
P60842, 406 residues long.
MolForge cross-references it against 0 known binders and
108 disease associations.
Target properties
| Protein name | Eukaryotic initiation factor 4A-I |
|---|
| UniProt accession | P60842 |
|---|
| Gene | EIF4A1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 406 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (108)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- mean platelet volume · score 0.16
- sex hormone-binding globulin measurement · score 0.15
- testosterone measurement · score 0.12
- metabolic syndrome · score 0.12
- autism spectrum disorder · score 0.12
- hepatocellular carcinoma · score 0.09
- diffuse large B-cell lymphoma · score 0.08
- neoplasm · score 0.08
- Mobius syndrome · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P60842-F1 | alphafold | PREDICTED | 87.05 | — |
Amino-acid sequence (406 residues)
MSASQDSRSR DNGPDGMEPE GVIESNWNEI VDSFDDMNLS ESLLRGIYAY GFEKPSAIQQ RAILPCIKGY DVIAQAQSGT GKTATFAISI LQQIELDLKA TQALVLAPTR ELAQQIQKVV MALGDYMGAS CHACIGGTNV RAEVQKLQME APHIIVGTPG RVFDMLNRRY LSPKYIKMFV LDEADEMLSR GFKDQIYDIF QKLNSNTQVV LLSATMPSDV LEVTKKFMRD PIRILVKKEE LTLEGIRQFY INVEREEWKL DTLCDLYETL TITQAVIFIN TRRKVDWLTE KMHARDFTVS AMHGDMDQKE RDVIMREFRS GSSRVLITTD LLARGIDVQQ VSLVINYDLP TNRENYIHRI GRGGRFGRKG VAINMVTEED KRTLRDIETF YNTSIEEMPL NVADLI
Explore Eukaryotic initiation factor 4A-I with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets